Simple Concepts Research Group

Cheap Stock to Watch: Catalyst Pharmaceuticals (CPRX)

by | Oct 9, 2021 | Stock Picks

Catalyst Pharmaceuticals (CPRX) Company Overview & Stock Price Forecast

This article provides an updated analysis and stock rating for Catalyst Pharmaceuticals (CPRX) including an updated stock price target for October 2021. Additional data on the company’s earnings yield, price/earnings ratio, return on invested capital and YTD performance are discussed as well.

Updated October 2021
Catalyst Pharmaceuticals Fundamentals

Catalyst Pharmaceuticals Stock Rating

Stock Price Target: $9.12

In the section below, we discuss the earnings yield, P/E, return on invested capital and YTD performance for Catalyst Pharmaceuticals in comparison to the Biotechnology industry and the S&P 500.

Catalyst Pharmaceuticals is a Small Cap company with a Market Cap of $663.1M.

Earnings Yield

Catalyst Pharma.BiotechnologyS&P 500T-Bill (10Y)

The current earnings yield for Catalyst Pharma. is 19.68%, in comparison to 2.94% for the S&P 500 and 1.51% for the 10-year treasury bond. The median earnings yield for the Biotechnology industry is 1.78%.

Price/Earnings Ratio

Catalyst Pharma.BiotechnologyS&P 500

Catalyst Pharma. is currently trading at a P/E of 9.33. The P/E for the Biotechnology industry is 31.01 and the P/E for the S&P 500 is 34.01.


Catalyst Pharma.BiotechnologyS&P 500

Catalyst Pharma. is currently trading at a P/S of 5.83. The P/S for the Biotechnology industry is 8.09 and the P/S for the S&P 500 is 3.09.


Catalyst Pharma.BiotechnologyS&P 500

Catalyst Pharma. is currently trading at a P/B of 4.00. The P/B for the Biotechnology industry is 7.18 and the P/B for the S&P 500 is 4.58.

Return on Invested Capital (ROIC)

Catalyst Pharma.BiotechnologyS&P 500

Catalyst Pharma. ROIC is currently 49.06% in comparison to 6.22% for the Biotechnology industry and 8.6% for the S&P 500.

YTD Performance

Catalyst Pharma.BiotechnologyS&P 500

The YTD performance for Catalyst Pharma. is 89.52%. The Biotechnology industry has a YTD performance of 11.79% in comparison to the YTD S&P 500 performance of 17.14%.

Recent Financial Results

  • Total revenues in Q2 2021 of $36.4M (23% increase from $29.6M in Q2 2020)
  • Firdapse product revenue of $33.6M (14% increase from $29.6 million prior year)
  • Operating income of $15.8M, up from $10.3 million YoY
  • R&D expenses reported of $4.5M (relatively unchanged YoY)
  • Repurchased 732,951 shares of common stock (totaling $3.7M)
  • Cash and cash equivalents of $155.3M; no funded debt.

Stock Price Target: $9.12

Company Overview

COMPANY Stock Rating

Catalyst Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing therapies for people with rare chronic neuromuscular and neurological diseases. The company has two proprietary drug offerings: Firdapse (used as a form of treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis) and Ruzurgi (used for the treatment of pediatric LEMS patients).

The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis and spinal muscular atrophy. It has license agreements with BioMarin Pharmaceutical and Endo Ventures Limited, for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Be sure to add these picks to your Watch List and if you haven’t done so already, check in on the performance of our Current Portfolio. Keep it simple and always do your due diligence.

This material is provided for informational purposes only and is not financial advice. The information contained herein should not solely be used for the formation of an investment decision, whether you are a long term or short term investor.